You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 167 No. 14, July 23, 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Investigation
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on ISI (1)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Prognosis/ Outcomes
 •Cardiovascular Disease/ Myocardial Infarction
 •Treatment Adherence
 •Adverse Effects
 •Alert me on articles by topic

Enoxaparin Dosing and Associated Risk of In-Hospital Bleeding and Death in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes

Nancy M. Allen LaPointe, PharmD; Anita Y. Chen, MS; Karen P. Alexander, MD; Matthew T. Roe, MD, MHS; Charles V. Pollack Jr, MD, MA; Barbara L. Lytle, MS; Magnus E. Ohman, MD; Brian W. Gibler, MD; Eric D. Peterson, MD, MPH

Arch Intern Med. 2007;167(14):1539-1544.

Background  The efficacy of enoxaparin sodium in non–ST-segment elevation acute coronary syndromes is well established; however, concerns remain regarding bleeding risk. The extent to which bleeding risk is attributable to excess dosing of enoxaparin is unclear.

Methods  Using data from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) National Quality Improvement Initiative, we determined the frequency of administration of excess (>10 mg above the recommended dose), lower-than-recommended (>10 mg below the recommended dose), and recommended doses of enoxaparin. We also determined unadjusted and adjusted risks of in-hospital major bleeding and death associated with excess and lower-than-recommended doses of enoxaparin.

Results  Of 10 687 patients, 2002 (18.7%) received an excess dose and 3116 (29.2%) received a lower-than-recommended dose of enoxaparin. Patients receiving excess doses were older (median age, 78 vs 66 years), smaller (median body mass index [calculated as weight in kilograms divided by height in meters squared], 26.2 vs 27.8), and more likely to be female (59.5% vs 38.2%) than patients receiving recommended doses (< .001 for all). After adjustment for baseline characteristics, an excess dose was significantly associated with major bleeding (odds ratio, 1.43; 95% confidence interval [CI], 1.18-1.75) and death (odds ratio, 1.35; 95% CI, 1.03-1.77) compared with a recommended dose. A lower-than-recommended dose was not associated with major bleeding (odds ratio, 1.01; 95% CI, 0.84-1.21), but there was a trend toward higher mortality (odds ratio, 1.25; 95% CI, 0.93-1.68).

Conclusions  Almost half the patients treated with enoxaparin did not receive a recommended dose and had worse outcomes, especially those receiving an excess dose. Improved adherence to the recommended dose could substantially improve the safety profile of enoxaparin.


Author Affiliations: Duke Clinical Research Institute (Drs Allen LaPointe, Alexander, Roe, Ohman, and Peterson and Mss Chen and Lytle) and Divisions of Clinical Pharmacology (Dr Allen LaPointe) and Cardiology (Drs Alexander, Roe, Ohman, and Peterson), Duke University Medical Center, Durham, North Carolina; Department of Emergency Medicine, Pennsylvania Hospital, University of Pennsylvania School of Medicine, Philadelphia (Dr Pollack); and Department of Emergency Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio (Dr Gibler).







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.